We are live on ! Find out more
RCKT icon

Rocket Pharmaceuticals
RCKT

178 hedge funds and large institutions have $1.96B invested in Rocket Pharmaceuticals in 2024 Q2 according to their latest regulatory filings, with 21 funds opening new positions, 74 increasing their positions, 50 reducing their positions, and 27 closing their positions.

New
Increased
Maintained
Reduced
Closed

64% more call options, than puts

Call options by funds: $5.17M | Put options by funds: $3.15M

48% more repeat investments, than reductions

Existing positions increased: 74 | Existing positions reduced: 50

1.56% less ownership

Funds ownership: 102.06% → 100.51% (-1.6%)

4% less funds holding

Funds holding: 186 → 178 (-8)

20% less funds holding in top 10

Funds holding in top 10: 5 → 4 (-1)

21% less capital invested

Capital invested by funds: $2.48B → $1.96B (-$522M)

22% less first-time investments, than exits

New positions opened: 21 | Existing positions closed: 27

Holders
178
Holders Change
-8
Holders Change %
-4.3%
% of All Funds
2.57%
Holding in Top 10
4
Holding in Top 10 Change
-1
Holding in Top 10 Change %
-20%
% of All Funds
0.06%
New
21
Increased
74
Reduced
50
Closed
27
Calls
$5.17M
Puts
$3.15M
Net Calls
+$2.02M
Net Calls Change
-$15.1M

Top Buyers

1
WP
Woodline Partners
California
+$12.9M
2
EC
EcoR1 Capital
California
+$11.7M
3
Vanguard Group
Vanguard Group
Pennsylvania
+$10.1M
4
Citadel Advisors
Citadel Advisors
Florida
+$8M
5
Westfield Capital Management
Westfield Capital Management
Massachusetts
+$7.9M

Top Sellers

1
ACA
Avoro Capital Advisors
New York
-$34M
2
State Street
State Street
Massachusetts
-$32.5M
3
LGM
Logos Global Management
California
-$21.8M
4
PA
Perceptive Advisors
New York
-$12.7M
5
CAM
Cormorant Asset Management
Massachusetts
-$8.08M
Name Holding Trade Value Shares
Change 		Change in
Stake
RIL
176
Rothschild Investment LLC
Illinois
$431 +$345 +15 +300%
Allspring Global Investments
177
Allspring Global Investments
North Carolina
$430 +$459 +20 New
ACA
178
Avoro Capital Advisors
New York
– -$34M -1,260,900 Closed
CAM
179
Cormorant Asset Management
Massachusetts
– -$8.08M -300,000 Closed
Qube Research & Technologies (QRT)
180
Qube Research & Technologies (QRT)
United Kingdom
– -$4.78M -177,524 Closed
CS
181
Candriam SCA
Luxembourg
– -$4.45M -165,000 Closed
NIP
182
Nicholas Investment Partners
California
– -$3.21M -119,137 Closed
SCM
183
Silverarc Capital Management
Massachusetts
– -$2.72M -101,002 Closed
AIG
184
American International Group
New York
– -$833K -30,918 Closed
Squarepoint
185
Squarepoint
New York
– -$734K -27,229 Closed
GGHC
186
Gilder Gagnon Howe & Co
New York
– -$519K -19,270 Closed
SRL
187
Scientech Research LLC
New Jersey
– -$427K -15,858 Closed
EFM
188
E Fund Management
China
– -$419K -15,549 Closed
TC
189
TwinBeech Capital
New York
– -$380K -14,122 Closed
ET
190
Entropy Technologies
New York
– -$365K -13,544 Closed
AI
191
Atom Investors
Texas
– -$309K -11,472 Closed
LCM
192
Legato Capital Management
California
– -$301K -11,159 Closed
AQR Capital Management
193
AQR Capital Management
Connecticut
– -$273K -10,118 Closed
GC
194
Guggenheim Capital
Illinois
– -$269K -9,985 Closed
XT
195
XTX Topco
Cayman Islands
– -$256K -9,507 Closed
CCA
196
Cobblestone Capital Advisors
New York
– -$242K -9,000 Closed
SG Americas Securities
197
SG Americas Securities
New York
– -$236K -8,765 Closed
HSBC Holdings
198
HSBC Holdings
United Kingdom
– -$217K -8,048 Closed
PRC
199
Pearl River Capital
Michigan
– -$208K -7,712 Closed
EAMA
200
EFG Asset Management (Americas)
Florida
– -$202K -7,500 Closed
5 6 7
8
9

RCKT Hedge Fund Activity: Q2 2024 in Review

178 of the 6,924 institutional investors tracked by Wall St. Rank reported a position in Rocket Pharmaceuticals (RCKT) for Q2 2024, worth a combined $1.96B — down 21% from $2.48B a quarter earlier.

Sellers outnumbered buyers: 27 funds closed out of RCKT and 21 opened new positions — a net loss of 6 holders — while 50 trimmed existing stakes and 74 added.

The largest buyer was Woodline Partners, opening a new position worth an estimated $12.9M. The largest seller was Avoro Capital Advisors, exiting entirely with an estimated $34M sold.

  • 178 institutional investors held Rocket Pharmaceuticals (RCKT) as of Q2 2024, down from 186 in Q1 2024.
  • Funds reported $1.96B of Rocket Pharmaceuticals stock for Q2 2024, down 21% quarter-over-quarter.
  • 21 funds opened new Rocket Pharmaceuticals positions in Q2 2024 and 27 closed out, a net change of -6 holders.
  • The largest Rocket Pharmaceuticals buyer in Q2 2024 was Woodline Partners, an estimated $12.9M added.
  • The largest Rocket Pharmaceuticals seller in Q2 2024 was Avoro Capital Advisors, an estimated $34M sold.

Based on aggregated 13F filings for Q2 2024.